MGX

Metagenomi Therapeutics, Inc. (MGX) | Rumor.io

Metagenomi Therapeutics

MGX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,043

Bullish sentiment (50-day avg)56%

Price to earnings ratio-0.49

Market capitalization43.1M

Earnings per share-2.49

Dividend yield (TTM)—

Revenue (annual)25.2M

Net income (annual)-87.9M

Social

What share of all stock conversation is about MGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

May 9

MGX, a 15% stakeholder in GameStop, has proposed a merger and acquisition deal.
The deal is contingent on eBay accepting MGX's offer, which may be the next best option for the company.
MGX is an Abu Dhabi state-backed investor, suggesting potential government backing for the deal.

Generated by AI

Sentiment

Of the messages about MGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +70	76.81% -20.62
Bearish	0%	0% 0	0% -70	23.19% +20.62

Bullish· Dec 10

$MGX has been upgraded to a buy from $7 to $14, indicating a significant increase in analyst confidence.
A trader achieved a 105% return on a swing trade, buying under $2 and selling at $4.10, suggesting the asset has strong trading potential.
Analysts predict $MGX could push for $5 or higher, with some even targeting $12, indicating a strong bullish sentiment among market participants.

Bearish· Jan 21

$MGX is susceptible to pump and dump schemes due to a misunderstanding of news that actually refers to a joint venture.
The company's BVPS is lower than its current price, making it a potentially overvalued investment.
The stock is likely to continue falling, with some predicting it will drop back to $3.00.

Generated by AI

Topics

Of the messages about MGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	12.9%	94.34%
Technical Analysis	—	—	87.1%	3.75%
Analysts	—	—	0%	0.04%
Controversies	—	—	0%	0.13%
Earnings	—	—	0%	0.47%
Macro	—	—	0%	1.28%

Feb 20

Metagenomi, Inc. (MGX) is involved in a deal with OpenAI, investing billions of dollars alongside Abu Dhabi's state-backed tech fund and Microsoft.
The deal is part of a broader partnership with Amazon, which could invest up to $50 billion, and includes the use of OpenAI models.
OpenAI is expected to rent data centers built by partners like Oracle, SoftBank, and MGX, converting the upfront expense to a lower operating expense over time.

Generated by AI

Community

Of the messages about MGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	37.5%	71.7%	4.63%
Newcomers	66.67%	62.5%	28.3%	95.37%

Sep 7

The newcomer is focused on the potential of Metagenomi, Inc. (MGX) to create millionaires through its stock performance.
The newcomer is discussing the concept of "chiplets" and its relation to Metagenomi, Inc. (MGX) and AMD.
The newcomer is highlighting the company Metagenomi, Inc. (MGX) and its stock symbol MGX, in contrast to AMD, which suggests a focus on MGX.

Generated by AI

News

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

29d agoBarchart.com

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about MGX also mention

#	Name	Attention
1	Power & Digital Infrastructure Acquisition II Corp.XPDB	0%0
2	Meridian Bioscience IncVIVO	0%0
3	Neuphoria Therapeutics Inc.NEUP	0%0
4	Mangoceuticals, Inc.MGRX	0%0
5	VivoPower International PLCVVPR	0%new
6	Bright Minds Biosciences Inc.DRUG	0%new
7	Quest Diagnostics IncorporatedDGX	0%0
8	AtlasClear Holdings, Inc.ATCH	0.01%0
9	TeraWulf Inc.WULF	0.02%-0.52
10	LifeVantage CorporationLFVN	0%new

Metagenomi Therapeutics, Inc.

Healthcare
Biotechnology

Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies. Its platform is designed to support precise DNA changes across a wide range of genetic targets, with current work centered on therapeutic programs for serious inherited conditions such as hemophilia and other genetic diseases. Metagenomi Therapeutics also collaborates with partners in biotechnology and pharmaceutical research to expand the potential uses of its editing technologies. Headquartered in Emeryville, California, Metagenomi Therapeutics, Inc. plays a role in the growing field of next-generation genetic medicine, where genome editing is being developed as a foundational approach to treating disease at its source.

Website

Location

5959 Horton Street

EmeryVille, CA, 94608

United States

Social

What share of all stock conversation is about MGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% +0

May 9

MGX, a 15% stakeholder in GameStop, has proposed a merger and acquisition deal.
The deal is contingent on eBay accepting MGX's offer, which may be the next best option for the company.
MGX is an Abu Dhabi state-backed investor, suggesting potential government backing for the deal.

Generated by AI

Sentiment

Of the messages about MGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +70	76.81% -20.62
Bearish	0%	0% 0	0% -70	23.19% +20.62

Bullish· Dec 10

$MGX has been upgraded to a buy from $7 to $14, indicating a significant increase in analyst confidence.
A trader achieved a 105% return on a swing trade, buying under $2 and selling at $4.10, suggesting the asset has strong trading potential.
Analysts predict $MGX could push for $5 or higher, with some even targeting $12, indicating a strong bullish sentiment among market participants.

Bearish· Jan 21

$MGX is susceptible to pump and dump schemes due to a misunderstanding of news that actually refers to a joint venture.
The company's BVPS is lower than its current price, making it a potentially overvalued investment.
The stock is likely to continue falling, with some predicting it will drop back to $3.00.

Generated by AI

Topics

Of the messages about MGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	12.9%	94.34%
Technical Analysis	—	—	87.1%	3.75%
Analysts	—	—	0%	0.04%
Controversies	—	—	0%	0.13%
Earnings	—	—	0%	0.47%
Macro	—	—	0%	1.28%

Feb 20

Metagenomi, Inc. (MGX) is involved in a deal with OpenAI, investing billions of dollars alongside Abu Dhabi's state-backed tech fund and Microsoft.
The deal is part of a broader partnership with Amazon, which could invest up to $50 billion, and includes the use of OpenAI models.
OpenAI is expected to rent data centers built by partners like Oracle, SoftBank, and MGX, converting the upfront expense to a lower operating expense over time.

Generated by AI

Community

Of the messages about MGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	37.5%	71.7%	4.63%
Newcomers	66.67%	62.5%	28.3%	95.37%

Sep 7

The newcomer is focused on the potential of Metagenomi, Inc. (MGX) to create millionaires through its stock performance.
The newcomer is discussing the concept of "chiplets" and its relation to Metagenomi, Inc. (MGX) and AMD.
The newcomer is highlighting the company Metagenomi, Inc. (MGX) and its stock symbol MGX, in contrast to AMD, which suggests a focus on MGX.

Generated by AI

Metagenomi Therapeutics

Social

May 9

Bullish· Dec 10

Bearish· Jan 21

Feb 20

Sep 7

Metagenomi director Laurence Reid buys $23,401 in company stock

Metagenomi general counsel Matthew Wein sells $414 in stock

Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock

Metagenomi at Wells Fargo conference: hemophilia program advances

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

Also Discussed

Metagenomi Therapeutics, Inc.

Company Information

Location

Metagenomi director Laurence Reid buys $23,401 in company stock

Metagenomi general counsel Matthew Wein sells $414 in stock

Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock

Metagenomi at Wells Fargo conference: hemophilia program advances

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

Also Discussed

Social

May 9

Bullish· Dec 10

Bearish· Jan 21

Feb 20

Sep 7